TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6256422

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) treatment in vivo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine incubation in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MP and histamine treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine (1 x 10(‐3) M) addition in vitro with MP
Number of subjects: 0
Study: 31817328

Group type: EXPERIMENTAL
Intervention: School-based anxiety prevention program
Number of subjects: 461

Group type: COMPARATOR
Intervention: School-as-usual control group
Number of subjects: 461
Study: 29132988

Group type: EXPERIMENTAL
Intervention: PnuBioVax (50, 200, 500 µg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PnuBioVax (200 µg and 500 µg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26652589

Group type: EXPERIMENTAL
Intervention: Depression Care for People with Cancer (DCPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24723075

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA)
Number of subjects: 2715

Group type: EXPERIMENTAL
Intervention: Low-dose statin (LDS)
Number of subjects: 2715

Group type: EXPERIMENTAL
Intervention: FA + Low-dose statin (LDS)
Number of subjects: 2715

Group type: EXPERIMENTAL
Intervention: Moderate-dose statin (MDS)
Number of subjects: 2715

Group type: EXPERIMENTAL
Intervention: FA + Moderate-dose statin (MDS)
Number of subjects: 2715

Group type: EXPERIMENTAL
Intervention: High-dose statin (HDS)
Number of subjects: 2715
Study: 21562420

Group type: EXPERIMENTAL
Intervention: 5 μg intrathecal hydromorphone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 μg intrathecal hydromorphone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 μg intrathecal hydromorphone
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.0 μg intrathecal hydromorphone (control group)
Number of subjects: 60
Study: 19708636

Group type: EXPERIMENTAL
Intervention: Debridement (Group A1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reattachment (Group A2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group A (overall)
Number of subjects: 20
Study: 17417700

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 or 5 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16393308

Group type: EXPERIMENTAL
Intervention: 7-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 7 days)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 4-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 4 days)
Number of subjects: 85
Study: 15372129

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11138570

Group type: EXPERIMENTAL
Intervention: 0.2 g x kg(‐1) sodium citrate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.4 g x kg(‐1) sodium citrate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.6 g x kg(‐1) sodium citrate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (calcium carbonate, 0.1 g x kg(‐1))
Number of subjects: 8
Study: 8780802

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (recombinant tissue plasminogen activator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1353679

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 52

Group type: COMPARATOR
Intervention: No Doxapram (Control)
Number of subjects: 52
Study: 6233481

Group type: EXPERIMENTAL
Intervention: Splenectomy (+) group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Splenectomy (−) group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Concanavalin‐A induced suppressor cells (ConAS) in peripheral blood lymphocytes (PBL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Spontaneous suppressor cells (SpS) in peripheral blood lymphocytes (PBL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: ConAS activities in spleen cells (SC)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: SpS activities in splenic vein lymphocytes (SVL)
Number of subjects: 2
Study: 30958844

Group type: EXPERIMENTAL
Intervention: Self-reported dental pain
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: Sociodemographic, clinical and behavioral/psychosocial indicators
Number of subjects: 1589
Study: 29095681

Group type: EXPERIMENTAL
Intervention: ConquerFear intervention (five face-to-face sessions)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Attention control (Taking-it-Easy relaxation therapy)
Number of subjects: 222
Study: 26825000

Group type: COMPARATOR
Intervention: 23vPPV
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 194

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 194
Study: 25011490

Group type: EXPERIMENTAL
Intervention: Caregivers of VaD patients
Number of subjects: 0
Study: 21970862

Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions delivered by a school nurse
Number of subjects: 37
Study: 19947265

Group type: EXPERIMENTAL
Intervention: Combined electroacupuncture and Chinese herb group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Electroacupuncture group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Chinese herb group
Number of subjects: 126
Study: 17368412

Group type: EXPERIMENTAL
Intervention: RITE intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 15111526

Group type: EXPERIMENTAL
Intervention: Telecare (glucometer transmission with feedback)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (glucometer transmission without feedback)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Meta-analysis of telecare trials
Number of subjects: 31
Study: 11525706

Group type: EXPERIMENTAL
Intervention: Crotalinae polyvalent immune Fab (Fab AV) - PRN group (as-needed)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Crotalinae polyvalent immune Fab (Fab AV) - Scheduled group (initial dose plus repeated treatments)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Crotalinae polyvalent immune Fab (Fab AV) - Follow-up
Number of subjects: 31
Study: 9589688

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg daily for 2 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8053577

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia without leg-warming (leg-skin temperature approximately 34 degrees C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Leg-skin temperature near 32 degrees C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Leg-skin temperature near 36 degrees C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Leg-skin temperature near 38 degrees C
Number of subjects: 6
Study: 2837304

Group type: EXPERIMENTAL
Intervention: Cereal fibre
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low fibre control diet
Number of subjects: 24
Study: 30608051

Group type: EXPERIMENTAL
Intervention: Azithromycin MDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 29182708

Group type: EXPERIMENTAL
Intervention: B-vitamin therapy (daily multivitamin with 5.0 mg folate, 1.0 mg vitamin B12, 50 mg vitamin B6)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo (daily multi-vitamin with no folate, 2.0 µg vitamin B12, 1.4 mg vitamin B6)
Number of subjects: 584
Study: 25003777

Group type: EXPERIMENTAL
Intervention: Meetup™
Number of subjects: 102

Group type: COMPARATOR
Intervention: American Heart Association condition
Number of subjects: 102
Study: 23615159

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with low-dose ASA (100 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with high-dose ASA (325 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with naproxen (500 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Edoxaban alone
Number of subjects: 126
Study: 21544078

Group type: EXPERIMENTAL
Intervention: NPO‐11 (L-menthol preparation)
Number of subjects: 0
Study: 19176561

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 2673

Group type: COMPARATOR
Intervention: No statin treatment (control)
Number of subjects: 2673
Study: 17917526

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 15153053

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reminder/recall
Number of subjects: 0
Study: 12556095

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% for three months and then as required
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% for six months on a regular basis
Number of subjects: 137
Study: 10080200

Group type: EXPERIMENTAL
Intervention: Angle‐supported anterior chamber intraocular lenses (PIOLs)
Number of subjects: 263
Study: 8526176

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 micrograms/24 hours
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beclomethasone (BDP) 800 micrograms/24 hours
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both drugs (BUD and BDP)
Number of subjects: 33
Study: 10147632

Group type: EXPERIMENTAL
Intervention: Conventional immunosuppression plus local graft irradiation (150 rads on days 1, 3, and 5)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional immunosuppression alone
Number of subjects: 100
Study: 6107099

Group type: EXPERIMENTAL
Intervention: Oral temazepam 20 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: i.v. diazepam (titrated doses)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both oral temazepam and i.v. diazepam
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oral temazepam
Number of subjects: 2
Study: 31039261

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program, sessions of 90 to 95 minutes, twice per week for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29021115

Group type: EXPERIMENTAL
Intervention: Embedded-BHC arm
Number of subjects: 333

Group type: COMPARATOR
Intervention: Pediatrician-only arm
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 333
Study: 27140797

Group type: EXPERIMENTAL
Intervention: Fasiglifam 50 mg
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Fasiglifam 400 mg
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 280
Study: 23497264

Group type: EXPERIMENTAL
Intervention: Telephone based intervention promoting positive lifestyle modifications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 21380493

Group type: EXPERIMENTAL
Intervention: Peer network-based intervention in intervention beer halls
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group in control beer halls
Number of subjects: 413
Study: 19412939

Group type: EXPERIMENTAL
Intervention: Early untreated PD subjects with clinically significant depressive symptoms (GDS-15 score > or = 5)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Early untreated PD subjects
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Subjects with mild depressive symptoms
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Increasing severity of depressive symptoms, older age, and longer PD duration
Number of subjects: 413
Study: 17400684

Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15460380

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment protocol
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 11349751

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention program
Number of subjects: 0
Study: 9310221

Group type: EXPERIMENTAL
Intervention: recombinant human interferon-beta la (r-hIFN-beta-1a)
Number of subjects: 124

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study: 8103982

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg IV every 6 hours)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 118
Study: 3746900

Group type: EXPERIMENTAL
Intervention: Autogenic Phrases
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) Biofeedback
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Thermal Biofeedback
Number of subjects: 136

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 136
Study: 31090592

Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood serum (allo‐PBS) eye drops 8 times a day for 30 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cord blood serum (CBS) eye drops 8 times a day for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both treatments (allo‐PBS and CBS)
Number of subjects: 30
Study: 28730743

Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 125

Group type: COMPARATOR
Intervention: Inulin-type fructans (ITF)
Number of subjects: 125

Group type: COMPARATOR
Intervention: ITF + Whey protein
Number of subjects: 125

Group type: COMPARATOR
Intervention: ITF
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study: 26465290

Group type: COMPARATOR
Intervention: Standard fluid protocol (10ml/kg/hr)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Restricted fluid protocol (5ml/kg/hr)
Number of subjects: 66
Study: 23354282

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 20658564

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19815891

Group type: EXPERIMENTAL
Intervention: 21-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 21-day doxycycline (200 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10-day doxycycline (200 mg/day)
Number of subjects: 57
Study: 17713336

Group type: EXPERIMENTAL
Intervention: 550 ppm F/pH 5.5 dentifrice
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F/NaF/silica, pH 5.5
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F/NaF/silica, pH 7.0
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1,100 ppm F/NaF/silica, pH 6.5 (gold standard)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1,500 ppm F/MFP/CaCO3, pH 9.5
Number of subjects: 19
Study: 15121364

Group type: EXPERIMENTAL
Intervention: Total anterior capsule cover (360 degrees) of the optic
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: No anterior capsule cover (360 degrees) of the optic
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Partial anterior capsule cover (<360 degrees) of the optic
Number of subjects: 202
Study: 11287037

Group type: EXPERIMENTAL
Intervention: CYP11a (tttta)(n) repeat‐polymorphism genotype
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Absence of the four‐repeat‐units allele (4R‐‐ genotype)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Serum hormone concentrations in 4R‐‐ individuals
Number of subjects: 125
Study: 9444504

Group type: EXPERIMENTAL
Intervention: Individual mannequins (Actar 911 and Laerdal Little Anne)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (sophisticated mannequin - Laerdal Recording Resusci Anne)
Number of subjects: 165
Study: 12959309

Group type: EXPERIMENTAL
Intervention: Nisoldipine (1, 2, 4 microg kg(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nifedipine (2.5, 5, 10 microg kg(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nisoldipine (2 microg kg(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nifedipine (10 microg kg(‐1))
Number of subjects: 15
Study: 3427209

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg (fed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg (fasted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (fed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (various doses)
Number of subjects: 12
Study: 2203940

Group type: EXPERIMENTAL
Intervention: Chemotherapy (including PCVm and ACVD regimens)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Addition of PCVm (cisplatinum, cyclophosphamide, Vm 26) to ACVD (adriamycine, cyclophosphamide, vincristine, dacarbazine) in trial NB 82
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (NB 82)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Shorter intervals for realization of chemotherapy (NB 85)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 340
Study: 165029

Group type: EXPERIMENTAL
Intervention: tibric acid 1,000 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: tibric acid 1,250 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: tibric acid 500 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: tibric acid 750 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: tibric acid (all doses)
Number of subjects: 50
Study: 31612281

Group type: EXPERIMENTAL
Intervention: Vaginal Er:YAG laser therapy
Number of subjects: 33
Study: 28723333

Group type: EXPERIMENTAL
Intervention: Enhanced antimicrobial prophylaxis (continuous trimethoprim-sulfamethoxazole, at least 12 weeks of isoniazid-pyridoxine, 12 weeks of fluconazole, 5 days of azithromycin, single dose of albendazole)
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Standard prophylaxis (trimethoprim-sulfamethoxazole alone)
Number of subjects: 1805
Study: 25283502

Group type: EXPERIMENTAL
Intervention: TiN coated TKP
Number of subjects: 101

Group type: COMPARATOR
Intervention: Uncoated TKP
Number of subjects: 101
Study: 24219768

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) intervention delivered by mental health professionals (n=126)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) intervention delivered by peer providers (n=43)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) intervention delivered by paraprofessionals (n=41)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=42)
Number of subjects: 252
Study: 21603894

Group type: EXPERIMENTAL
Intervention: Restraint group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Disinhibition group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 19626559

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) interventions in brain injury rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled trial (RCT) methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions in brain injury rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethical practice in brain injury rehabilitation
Number of subjects: 0
Study: 16490894

Group type: EXPERIMENTAL
Intervention: Local anesthesia with monitored anesthesia care (MAC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Local anesthesia with MAC
Number of subjects: 58
Study: 15103454

Group type: EXPERIMENTAL
Intervention: Hip protectors (n=276)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Control group (n=285)
Number of subjects: 561
Study: 11194529

Group type: EXPERIMENTAL
Intervention: Tofu diet (290 grams per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Meat diet (150 grams per day)
Number of subjects: 42
Study: 9051538

Group type: EXPERIMENTAL
Intervention: LMA removal during anesthesia (before airway reflexes return)
Number of subjects: 333

Group type: COMPARATOR
Intervention: LMA removal after return of airway reflexes
Number of subjects: 333
Study: 8395315

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg in the morning and at bedtime
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Antibacterial drugs (gentamicin, terramycin, furazolidone, berberine)
Number of subjects: 90
Study: 2439568

Group type: EXPERIMENTAL
Intervention: ARA-AMP 10 mg/kg/day for 5 days followed by 5 mg/kg/day for 23 days (15 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No treatment (14 patients)
Number of subjects: 29
Study: 29751239

Group type: EXPERIMENTAL
Intervention: Deprexis (12-week psychological online intervention)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 577
Study: 28254962

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (up to 2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous propofol (up to 2.5 mg/kg)
Number of subjects: 0
Study: 25617503

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 20 mg/kg/day
Number of subjects: 40
Study: 23758305

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided three-in-one femoral nerve block plus morphine (FNB group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (placebo plus morphine) (SC group)
Number of subjects: 36
Study: 19304860

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 18928094

Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI) 1.5 mL/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI)
Number of subjects: 50